Kidney Cancer Clinical Trials 2023

Kidney Cancer Clinical Trials 2023

Kidney Cancer research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in kidney cancer clinical trials today.

Kidney Cancer Clinical Trials

Here are the 6 most popular medical studies for kidney cancer

Popular filter options for kidney cancer trials

Kidney Cell Carcinoma Clinical Trials

View 54 Kidney Cell Carcinoma medical studies.

Renal Cell Cancer Clinical Trials

View 54 Renal Cell Cancer medical studies.

Metastatic Kidney Cancer Clinical Trials

View 83 metastatic kidney cancer medical studies.

PD-1 Positive Clinical Trials

View 11 PD-1 positive medical studies.

PD-L1 Positive Clinical Trials

View 11 PD-L1 positive medical studies.

Phase 3 Kidney Cancer Clinical Trials

View 83 phase 3 kidney cancer medical studies.

Kidney Cancer Clinical Trials With No Placebo

View 83 kidney cancer medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to kidney cancer

What are the top hospitals conducting kidney cancer research?

When it comes to advancing the treatment options for kidney cancer, several top hospitals across the United States are leading the charge. In Sacramento, California, the University of California Davis Comprehensive Cancer Center is currently conducting 11 active clinical trials focused on kidney cancer. Although they have a relatively lower number of all-time trials at just 10, their dedication to this field began in 2006 when they recorded their first-ever kidney cancer trial.

Moving down south to Los Angeles, USC / Norris Comprehensive Cancer Center is making significant contributions as well. With 10 ongoing kidney cancer trials and eight completed trials thus far, this institution has been actively exploring innovative solutions since their initial involvement in renal cancer research back in 2009.

On the opposite coast, Boston's prestigious Dana Farber Cancer Institute showcases its commitment to combating kidney cancer with eight active clinical trials and an impressive history of 11 previous studies conducted since initiating their inaugural trial in 2014. Meanwhile, another renowned facility located within Boston—the Dana-Farber Cancer Institute—has also made substantial strides in understanding and treating this condition. They have achieved a remarkable track record of eight ongoing clinical trials and a substantial contribution of twenty-two completed studies since embarking on their first-ever kidney cancer trial way back in1995.

Rounding out our list is New York City's Memorial Sloan Kettering Cancer Center which shares similar accomplishments with eight active kidney cancer trials underway and an extensive portfolio that includes twenty-three previously conducted studies dating back to their inaugural trial recorded in2000.

These leading hospitals collectively demonstrate unwavering determination to combat one of the most common types of cancers worldwide – Kidney Cancer. By continuously pushing boundaries through groundbreaking research initiatives and cutting-edge clinical trials these institutions bring hope not only for current patients but also for those yet to face such challenging situations; ultimately paving a path towards better treatments, improved outcomes,and brighter futures for individuals affected by this disease globally.

Which are the best cities for kidney cancer clinical trials?

When it comes to kidney cancer clinical trials, several cities excel in research and development. Los Angeles, California leads the pack with 58 active trials focusing on treatments like everolimus, Avelumab (MSB0010718C), and Nephrectomy. Boston, Massachusetts, California leads the pack with 58 active trials focusing on treatments like everolimus, Avelumab (MSB0010718C), and Nephrectomy. Boston, Massachusetts closely follows with 42 ongoing studies investigating Ipilimumab, Nivolumab, Avelumab (MSB0010718C), and more. Denver, Colorado also makes a mark with 30 active trials exploring Pharmacological Study, everolimus, Cabozantinib among others. These cities offer individuals battling kidney cancer access to cutting-edge clinical trials that pave the way for advancements in care and hope for better outcomes.

Which are the top treatments for kidney cancer being explored in clinical trials?

Exciting advancements in kidney cancer research have led to the exploration of several promising treatments in clinical trials. Nivolumab, a groundbreaking drug first listed in 2014, is currently being tested in five active trials and has been involved in a total of 20 kidney cancer trials so far. Another contender making waves is ipilimumab with four ongoing trials and ten all-time kidney cancer studies since its introduction in 2014. In addition, cabozantinib shows promise with four active and six all-time kidney cancer trials since its listing in 2012. Last but not least, pembrolizumab joins the ranks with three active and nine all-time kidney cancer studies since it was introduced to the scene in 2015. These innovative treatments offer hope for improved outcomes for patients fighting this formidable disease.

What are the most recent clinical trials for kidney cancer?

Exciting developments have emerged in recent clinical trials for kidney cancer, offering new possibilities for treatment. One noteworthy trial involves the evaluation of a triplet combination therapy in phase 2, showing potential efficacy against kidney cancer. Another promising study focuses on cabozantinib, also in phase 2, as a potential therapeutic option for patients with this type of cancer. Additionally, interventions aimed at improving outcomes and patient care continue to be explored through a phase 4 trial. These advancements highlight the ongoing commitment to finding effective treatments for kidney cancer and bring hope to those affected by this challenging disease.

What kidney cancer clinical trials were recently completed?

Several recent clinical trials have provided valuable insights into the treatment of kidney cancer. Notably, in October 2020, UNC Lineberger Comprehensive Cancer Center concluded a trial investigating Perflutren lipid microsphere's potential benefits. Preceding this, in September 2019, another trial sponsored by the same institution explored Perflutren lipid microsphere for kidney cancer. Earlier studies include M.D. Anderson Cancer Center's examination of Sitravatinib in April 2017 and Ludwig Institute for Cancer Research's investigation of Tremelimumab in December 2016. Further research includes Novartis Pharmaceuticals' study on PDR001 (completed October 2016), National Cancer Institute's exploration of INC280 (completed January 2014), NCI's evaluation of Cabozantinib (completed September 2012), and M.D. Anderson Cancer Center's analysis of Axitinib (completed February 2011). These comprehensive investigations contribute to expanding our understanding and advancing treatment options for patients with kidney cancer.